RSV vaccine study for people with weakened immune systems
Part of Infections clinical trials.
This study tests how well an RSV vaccine (Arexvy) works in people whose immune systems are weakened by certain cancers, autoimmune diseases, or treatments. It aims to see if the vaccine can protect these vulnerable groups from respiratory infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older (or 60 or older for the healthy group).
- You must have a weakened immune system from conditions like certain blood cancers, lung cancer, or autoimmune diseases like rheumatoid arthritis or inflammatory bowel disease.
- You must be on or about to start treatment for your condition (or have a stable condition).
- You must be able to care for yourself and live at home or in a place with minimal help.
- Women who can have children must use birth control and have a negative pregnancy test before the first vaccine dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a booster dose of an experimental RSV vaccine (SCB-1019T) in healthy adults aged 60-85 who have already received the approved RSV vaccine AREXVY. The goal is to see if the booster is safe and boosts your immune system.
This study tests an RSV vaccine in people with weakened immune systems (like transplant recipients) and in older adults. It aims to see how well the vaccine boosts protection against RSV, a common respiratory virus.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
Hear when a new RSV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.